Lacto-N-tetraose
Modify Date: 2025-08-25 13:16:02
Lacto-N-tetraose structure
|
Common Name | Lacto-N-tetraose | ||
|---|---|---|---|---|
| CAS Number | 14116-68-8 | Molecular Weight | 707.63000 | |
| Density | 1.76g/cm3 | Boiling Point | 1116.1ºC at 760 mmHg | |
| Molecular Formula | C26H45NO21 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 628.8ºC | |
Use of Lacto-N-tetraoseLacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula[1]. |
| Name | lacto-n-tetraose |
|---|---|
| Synonym | More Synonyms |
| Description | Lacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula[1]. |
|---|---|
| Related Catalog | |
| In Vitro | HMOs exhibits antimicrobial and antibiofilm activity against Streptococcus agalactiae, antibiofilm activity against Methicillin-resistant Staphylococcus aureus (MRSA), and antimicrobial activity against both Acinetobacter baumannii and Clostridium difficile[2]. Lacto-N-tetraose (500-2000 μg/mL) does not cause clastogenic or aneugenic signs in human peripheral blood lymphocytes, nor increase the percentage of micronucleated cells[3]. |
| In Vivo | Lacto-N-tetraose (1000-4000 mg/kg; p.o.; daily for 90 days) does not show toxicity in neonatal SD rats[3]. Animal Model: Female neonatal SD rats (housed together with dam until weaning after 21 days)[3] Dosage: 1000, 25000 and 4000 mg/kg Administration: p.o.; daily for 90 days Result: Did not show toxicity on clinical observations, body weight, food consumption, development and maturation, clinical pathology, organ weights or histopathology. |
| References |
| Density | 1.76g/cm3 |
|---|---|
| Boiling Point | 1116.1ºC at 760 mmHg |
| Molecular Formula | C26H45NO21 |
| Molecular Weight | 707.63000 |
| Flash Point | 628.8ºC |
| Exact Mass | 707.24800 |
| PSA | 356.70000 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.668 |
| InChIKey | AXQLFFDZXPOFPO-OYNOJIEESA-N |
| SMILES | CC(=O)NC1C(OC2C(O)C(CO)OC(OC3C(CO)OC(O)C(O)C3O)C2O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O |
| Safety Phrases | 24/25 |
|---|
| fromhumanmilk |
| GAL-BETA1,3GLCNAC-BETA1,3GAL-BETA1,4GLC |
| LNT-GEL |
| LNT |
| LACTO-N-TETRAOSE FROM HUMAN MILK |
| LCOSE4 |
| LNT-KLH |